• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to footer
  • Canada
  • United Kingdom
  • Subscribe
  • facebook
  • instagram
  • RSS
  • RSMUS.com

The Real Economy Blog

Search

  • Economics
  • Technology
  • Consumer
  • Industrials
  • Finance
  • Real Estate
  • Health Care
  • Life Sciences
Home > Life Sciences > Better data use has pros and cons for life sciences

Better data use has pros and cons for life sciences

Dec. 13, 2018 by Matt Wolf

  • email
  • Twitter
  • Facebook
  • Linkedin

Life science graphicThe volume and variety of health care data should expand significantly in 2019. Specifically, we will be monitoring growth in data sources outside those collected from traditional electronic health records, including information gleaned from wearable technology and direct-to-consumer genetic testing. Life science companies should consider how best to leverage this growing trove of information as they seek to more quickly bring effective and personalized therapies, drugs and devices to market, while simultaneously managing inherent cybersecurity risks. The global personalized medicine market is expected to reach $194.4 billion by 2024 from an estimated $92.4 billion in 2017, according to research from ResearchandMarkets.com.

Data is the fuel that powers artificial intelligence and machine learning, which both represent significant opportunities for life science. A recent study from Carnegie Mellon suggests that AI could reduce the cost of drug development by 70 percent. The technology is already capable of shortening the lead-time required to source candidates for cancer treatment clinical trials to mere weeks from years. Data, however, also represents a liability. Not only is medical information highly regulated by HIPAA, HITRUST, GDPR and other laws, it is also extremely valuable. A 2013 report issued by the FBI estimates that medical data is 50 times more valuable than social security numbers to bad actors on the black markets of the internet.

The Department of Health and Human Services estimates that hackers—not theft or careless employees—are responsible for 75 percent of health care data breaches involving 500 or more individuals.

We expect middle market companies to leverage this opportunity through strategic alliances with contract research organizations or other partners. In fact, based on a recent survey we jointly conducted with the Center for Business Intelligence, nearly 80 percent of development companies employ these relationships. Unfortunately, these arrangements do not necessarily limit the liability related to a data breach or cyberattack. The regulatory environment generally implicates partners and business associates in such incidents. We will continue to monitor the relationship between the risks and opportunities big data presents to the middle market life sciences sector in 2019 and beyond.

  • email
  • Twitter
  • Facebook
  • Linkedin

Related posts

  • Data breaches are down but more effective

    While the number of data breaches per year has doubled in the last decade, there were significantly fewer breaches in 2018 compared to 2017 (see chart below). Unfortunately, cybercriminals have had greater success in accessing sensitive personal and…

  • A data scientist could keep Amazon from kicking you off its platform

    On May 28, Bloomberg reported that Amazon may stop taking wholesale orders from smaller vendors, a move intended to drive efficiencies and ensure that the tech giant maintains healthy supplies of its most in-demand products. Whether or not…

  • restaurant
    Data to help food makers manage trends, boost transparency

    The 2019 outlook for the food and beverage sector remains cautiously optimistic; however, macroeconomic trends and public policy headwinds make it increasingly important for middle market companies to pay close attention to consumer preferences, while leveraging technology to…

Filed Under: Life Sciences

About Matt Wolf

@MattWolfHC

Matt leads RSM’s health care valuation consulting group. In this capacity, Matt helps health care clients evaluate mergers, acquisitions, joint ventures, and other growth strategies.

In January 2018, Matt was selected as a senior analyst RSM’s cutting edge Industry Eminence Program, which positions its senior analysts to understand, forecast and communicate economic, business and technology trends shaping the industries RSM serves. These senior analysts advise clients on conditions impacting middle market leaders. Matt’s focus is the health care and life sciences space.

Primary Sidebar

Other Regions

  • Canada
  • United Kingdom

Categories

  • Economics
  • Technology
  • Consumer Products
  • Industrials
  • Financial Services
  • Real Estate
  • Health Care
  • Life Sciences

Recent Life Science articles

5 things to know in life sciences: Week of March 1

Mar. 4, 2021

5 things to know in life sciences: Week of Feb. 22

Feb. 26, 2021

5 things to know in life sciences: Week of Feb. 15

Feb. 19, 2021

RSMUS.com links

The Real Economy

Middle Market Business Index

MMBI Special Reports

Footer

  • Facebook
  • Instagram
  • RSS

About The Real Economy Blog

The Real Economy Blog from RSM US LLP was developed to provide timely economic insights about the middle market economy. It is offered as a complement to RSM’s macroeconomic thought leadership, including The Real Economy monthly publication and the proprietary RSM US Middle Market Business Index (MMBI).

© 2021 RSMUS.com | Privacy Policy | Cookie Policy

The Real Economy Blog
  • Economics
  • Technology
  • Consumer
  • Industrials
  • Finance
  • Real Estate
  • Health Care
  • Life Sciences